Pharmacokinetic Evaluation of AMX0035 in Subjects with Hepatic Impairment and Healthy Controls

The primary objective of this study is to evaluate the **pharmacokinetics** of AMX0035 in participants with impaired hepatic function compared to healthy participants. This is clinically relevant as it aims to understand how hepatic impairment affects the absorption, distribution, metabolism, and excretion of AMX0035, which is crucial for determining appropriate dosing and ensuring safety and efficacy in this population.

The clinical trial involves **volunteers with hepatic impairment** as well as healthy volunteers. The study population includes both male and female participants, with an age range corresponding to categories 3 and 4, which typically represent adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their health status, specifically targeting those with hepatic impairment and healthy individuals. No specific lifestyle considerations such as diet, physical activity, or habits have been highlighted as relevant to the study. Key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the pharmacokinetics of AMX0035 in participants with **hepatic impairment** and healthy volunteers. This study is a Phase 3, randomized, double-blind, controlled trial. The estimated duration of the trial spans from August 1, 2023, to March 17, 2024. Participants will be involved in a series of study visits, beginning with an inclusion visit, which serves as the screening phase to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into either the treatment or control group.

Throughout the trial, participants will attend multiple follow-up visits, which are scheduled to monitor safety, collect pharmacokinetic data, and assess any adverse events. These visits are crucial for ensuring participant safety and the integrity of the data collected. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted, and any remaining study-related procedures are completed.

The expected length of participant involvement is approximately seven months, contingent upon adherence to the study protocol. Conditions that may lead to early termination from the study include significant protocol deviations, adverse events that compromise participant safety, or voluntary withdrawal by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. Additionally, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, that may be used in the study. Furthermore, the documentation lacks details on drug administration, dosing schedules, and participant compliance monitoring. As such, no further description of the treatments used in this clinical trial can be provided based on the available data.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 1, 2023, with an estimated completion date of March 17, 2024. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters at predetermined timepoints throughout the study duration. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy assessments. The results will contribute to the understanding of the treatment's impact on the specified medical condition, although the condition itself is not specified in the available data.